Peptonic Medical’s vaginal gel shows an excellent safety profile and reduces symptoms associated with urinary incontinence
Stockholm, May 29th, 2017. Peptonic Medical AB (publ) today announces additional results of the completed phase 2b study that show that the vaginal gel – without oxytocin – is well tolerated and its use doesn’t cause any serious adverse events (SAE). During the course of the study (including the main study and the exploratory part), only one SAE was reported among the total of 90 study subjects. This SAE, however, was deemed as ‘not related’ (to the treatment) as it concerned a study subject falling from a horse back. One reported AE was deemed as ‘probably related’ to the treatment. In